


Osteoarthritis Pharmaceutical and Healthcare Pipeline Review H2

Osteoarthritis Treatment Pipeline Review H2 2016

PUNE, INDIA, January 6, 2017
/EINPresswire.com/ -- GET SAMPLE REPORT @

<https://www.wiseguyreports.com/sample-request/768792-opportunityanalyzer-osteoarthritis-opportunity-analysis-and-forecasts-to-2024>

Opportunity Analyzer: Osteoarthritis - Opportunity Analysis and Forecasts to 2024



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com
☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>
🐦 <https://twitter.com/WiseGuyReports>
📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Summary

Osteoarthritis (OA) is a slowly progressive joint disease that is typically seen in middle-aged to elderly people. The disease is caused by the breakdown of the joint cartilage due to mechanical stress or biochemical alterations, which causes the bone underneath to fail. OA can occur together with other types of arthritis, such as gout or rheumatoid arthritis (RA). OA tends to affect commonly used joints such as the hands and spine as well as the weight-bearing joints such as the hips and knees. The causes of OA are not fully understood. However, genetic factors, and damage to the joints, either through repeated excessive loading and stress of a joint over time (for example, the knee joint in an obese person) or by injury (such as a break or dislocation of a finger joint) increases the risk of developing OA. There is no single test to diagnose OA. Several methods are used to diagnose OA and to rule out other problems: medical history, physical exam, X-rays, blood tests, or joint fluid analysis. The structural changes that occur with old age may not be accompanied by symptoms, which makes the estimation of the prevalence of OA difficult.

Scope

- Overview of OA, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized OA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the OA therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global OA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Table of Contents

1	Table of Contents	10
1.1	List of Tables	14
1.2	List of Figures	18
2	Introduction	19
2.1	Catalyst	19
2.2	Related Reports	20
3	Disease Overview	21
3.1	Etiology and Pathophysiology	21
3.1.1	Etiology	21
3.1.2	Pathophysiology	24
3.2	Symptoms	26
4	Epidemiology	27
4.1	Disease Background	27
4.2	Risk Factors and Comorbidities	28
4.3	Global and Historical Trends	30
4.3.1	Total Prevalence of OA - 7MM	30
4.3.2	Diagnosed Prevalence of OA - 7MM	30
4.3.3	US	31
5	Current Treatment Options	90
5.1	Overview	90
5.2	Product Profiles - Major Therapies	92
5.2.1	NSAIDs (Numerous Branded and Generic Products)	92
5.2.2	Topical Therapies (Numerous Branded and Generic Products)	96
5.2.3	Opioids (Numerous Branded and Generic Products)	101
5.2.4	Antidepressants (Numerous Branded and Generic Products)	106
5.2.5	Intra-Articular Corticosteroid Injections (Numerous Branded and Generic Products)	108
6	Unmet Needs Assessment and Opportunity Analysis	112
6.1	Overview	112
6.2	Analgesic Drugs that Adequately Address Pain	113
6.3	Disease-Modifying Drugs	115
6.4	Drugs with Improved Tolerability for Use in the Elderly Patient Population	116
6.5	Improved Implementation of Guidelines on Non-pharmaceutical Treatments	117
7	Research and Development Strategies	121
7.1	Overview	121
7.2	Development of Pharmacological Treatments with Novel MOAs	121
7.3	Development of Disease-Modifying OA Drugs	122
7.4	Strategic Partnerships	123
7.5	Current Clinical Trial Design	124
8	Pipeline Assessment	129
8.1	Overview	129
8.2	Promising Drugs in Clinical Development	130
8.2.1	Ampion	130
8.2.2	NKTR-181	134
9	Pipeline Valuation Analysis	162
9.1	Clinical Benchmarking of Key Pipeline Drugs	162
9.2	Commercial Benchmark of Key Pipeline Drugs	163
...	Continued	

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/768792-opportunityanalyzer-osteoarthritis-opportunity-analysis-and-forecasts-to-2024>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.